These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2298 related items for PubMed ID: 26072109

  • 1. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators.
    Lancet; 2015 Aug 08; 386(9993):541-51. PubMed ID: 26072109
    [Abstract] [Full Text] [Related]

  • 2. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
    Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group.
    N Engl J Med; 2016 Jul 28; 375(4):345-56. PubMed ID: 27299809
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.
    Am J Clin Dermatol; 2017 Apr 28; 18(2):273-280. PubMed ID: 28074446
    [Abstract] [Full Text] [Related]

  • 4. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R, OPT Compare Investigators.
    Lancet; 2015 Aug 08; 386(9993):552-61. PubMed ID: 26051365
    [Abstract] [Full Text] [Related]

  • 5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 08; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K.
    J Eur Acad Dermatol Venereol; 2017 Oct 08; 31(10):1686-1692. PubMed ID: 28322474
    [Abstract] [Full Text] [Related]

  • 7. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB.
    Lancet; 2017 Jul 15; 390(10091):276-288. PubMed ID: 28596043
    [Abstract] [Full Text] [Related]

  • 8. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM.
    Br J Dermatol; 2018 Mar 15; 178(3):674-681. PubMed ID: 28991370
    [Abstract] [Full Text] [Related]

  • 9. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, Kerr L, Sofen H.
    J Dermatolog Treat; 2017 Jun 15; 28(4):282-287. PubMed ID: 27759463
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.
    Lancet; 2018 Aug 25; 392(10148):650-661. PubMed ID: 30097359
    [Abstract] [Full Text] [Related]

  • 11. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep 25; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 12. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S.
    N Engl J Med; 2012 Mar 29; 366(13):1190-9. PubMed ID: 22455413
    [Abstract] [Full Text] [Related]

  • 13. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB.
    JAMA Dermatol; 2016 Jun 01; 152(6):661-9. PubMed ID: 26953848
    [Abstract] [Full Text] [Related]

  • 14. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P.
    J Eur Acad Dermatol Venereol; 2017 Mar 01; 31(3):477-482. PubMed ID: 27910156
    [Abstract] [Full Text] [Related]

  • 15. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C.
    J Eur Acad Dermatol Venereol; 2017 Jul 01; 31(7):1196-1207. PubMed ID: 28370467
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
    Blauvelt A, Gooderham M, Iversen L, Ball S, Zhang L, Agada NO, Reich K.
    J Am Acad Dermatol; 2017 Nov 01; 77(5):855-862. PubMed ID: 28917383
    [Abstract] [Full Text] [Related]

  • 17. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group, FIXTURE Study Group.
    N Engl J Med; 2014 Jul 24; 371(4):326-38. PubMed ID: 25007392
    [Abstract] [Full Text] [Related]

  • 18. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
    Valenzuela F, de la Cruz Fernandez C, Galimberti RL, Gürbüz S, McKean-Matthews M, Goncalves L, Romiti R.
    Actas Dermosifiliogr; 2017 Jul 24; 108(6):550-563. PubMed ID: 28342534
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS, Seyger MMB, Alejandro Magariños G, Bagel J, Pinter A, Cather J, Keller S, Rodriguez Capriles C, Gontijo Lima R, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K, IXORA-PEDS study group.
    Br J Dermatol; 2020 Aug 24; 183(2):231-241. PubMed ID: 32316070
    [Abstract] [Full Text] [Related]

  • 20. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
    Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W, Acharya N, Rapaport MH.
    Psychother Psychosom; 2017 Aug 24; 86(5):260-267. PubMed ID: 28903122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 115.